126 related articles for article (PubMed ID: 2434791)
1. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.
Francis RJ; Brown AN; Kler L; Fasanella d'Amore T; Nussberger J; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1987 Jan; 9(1):32-8. PubMed ID: 2434791
[TBL] [Abstract][Full Text] [Related]
2. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
Nussberger J; Fasanella d'Amore T; Porchet M; Waeber B; Brunner DB; Brunner HR; Kler L; Brown AN; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):39-44. PubMed ID: 2434792
[TBL] [Abstract][Full Text] [Related]
3. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
Fasanella d'Amore T; Bussien JP; Nussberger J; Waeber B; Turini GA; Brunner HR; Kler L; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):26-31. PubMed ID: 2434790
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension.
Meredith PA; Elliott HL; Reid JL; Francis RJ
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):263S-266S. PubMed ID: 2548553
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and bioavailability of cilazapril in normal man.
Williams PE; Brown AN; Rajaguru S; Francis RJ; Walters GE; McEwen J; Durnin C
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):181S-188S. PubMed ID: 2527531
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function.
Shionoiri H; Gotoh E; Takagi N; Takeda K; Yabana M; Kaneko Y
J Cardiovasc Pharmacol; 1988 Feb; 11(2):242-9. PubMed ID: 2452321
[TBL] [Abstract][Full Text] [Related]
7. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers.
Lenfant B; Mouren M; Bryce T; De Lauture D; Strauch G
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S38-43. PubMed ID: 7527100
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic study of cilazapril in elderly and young volunteers.
Williams PE; Brown AN; Rajaguru S; Walters GE; McEwen J; Durnin C
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):211S-215S. PubMed ID: 2527535
[TBL] [Abstract][Full Text] [Related]
9. Review of studies on the clinical pharmacodynamics of cilazapril.
Belz GG; Breithaupt K; Erb K
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S14-9. PubMed ID: 7898090
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cilazapril during repeated oral dosing in healthy young volunteers.
Williams PE; Brown AN; Rajaguru S; Francis RJ; Bell AJ; Dewland PM
Eur J Drug Metab Pharmacokinet; 1990; 15(1):63-7. PubMed ID: 2166672
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide.
Krum H; Jackson B; Conway EL; Howes LG; Johnston CI; Louis WJ
J Cardiovasc Pharmacol; 1992 Sep; 20(3):451-7. PubMed ID: 1279292
[TBL] [Abstract][Full Text] [Related]
13. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
Visser M; Holinka CF; Coelingh Bennink HJ
Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
[TBL] [Abstract][Full Text] [Related]
14. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
Waterfall JF
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics and dose proportionality of cilazapril.
Massarella J; DeFeo T; Lin A; Limjuco R; Brown A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):199S-204S. PubMed ID: 2527533
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic study of cilazapril in patients with congestive heart failure.
Rosenthal E; Francis RJ; Brown AN; Rajaguru S; Williams PE; Steiner J; Curry PV
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):267S-273S. PubMed ID: 2548554
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848).
Gross V; Treher E; Haag K; Neis W; Wiegand U; Schölmerich J
J Hepatol; 1993 Jan; 17(1):40-7. PubMed ID: 8445218
[TBL] [Abstract][Full Text] [Related]
18. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril.
Massarella JW; DeFeo TM; Brown AN; Lin A; Wills RJ
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):205S-209S. PubMed ID: 2527534
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cilazapril in patients with renal failure.
Fillastre JP; Moulin B; Godin M; Williams PE; Brown AN; Francis RJ; Pinta P; Manfredi R
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):275S-282S. PubMed ID: 2527539
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
